Jump to content
  • rrdiLogo384x64.jpg.3cd1bd79f5d066075bdd9

    Legal Disclaimer

    All use of the Rosacea Research & Development Institute (RRDi or irosacea.org) Web site is subject to the terms and conditions set forth below. When referring to the Rosacea Research & Development Institute (RRDi or irosacea.org) in this legal discaimer includes the following domains:


    Any use of such Web pages constitutes the user's agreement to abide by the following terms and conditions.

    The Rosacea Research & Development Institute [RRDi] is a non profit corporation registered in the states of Alabama and Hawaii, USA as well as recognized June 7, 2004 by the USA Internal Revenue Service as a 501 (c) (3) non profit tax exempt organization.

    All medical information on this Web site has been reviewed for accuracy. However, the information posted here by the Rosacea Research & Development Institute or any third party should not be considered medical advice, nor is it intended to replace consultation with a qualified physician. The Institute does not evaluate, endorse or recommend any particular medications, products, equipment or treatments. Rosacea may vary substantially from one patient to another, and treatment must be tailored by a physician for each individual case.

    Links to other Web sites found on irosacea.org are provided as a service to our users. Such linkage does not constitute endorsement of the site by the Rosacea Research & Development Institute, and the Institute is not responsible for the content of external web sites. Links to commercial rosacea web sites are prohibited at this time.

    The Rosacea Research & Development Institute Web pages are designed for educational purposes only. This information is not intended to substitute for informed medical advice. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified health care provider. The Rosacea Research & Development Institute does not endorse or attest to the validity or accuracy of any treatments or medications discussed herein. Before acting on any information contained on the Web pages, you agree that you will consult your health care provider to determine whether the information you are relying on is appropriate for your medical condition.

    All information provided by the Rosacea Research & Development Institute is owned by or licensed to the Rosacea Research & Development Institute. The Rosacea Research & Development Institute retains all proprietary rights to the information contained on the pages. Except for making one hard copy print of the information or downloading the material for a one-time use, information on the pages may not be reproduced, transmitted, distributed, or displayed, without the express consent of the Rosacea Research & Development Institute.



    The RRDi does not knowlingly use any material (images or text) that is copyrighted by others. If you believe any materials accessible on or from this web site infringe your copyright, you may request removal of those materials (or access thereto) from this web site by the RRDi copyright agent (identified below) and providing the following information:
    Identification of the copyrighted work that you believe to be infringed. Please describe the work, and where possible include a copy or the location (e.g., URL) of an authorized version of the work. Identification of the material that you believe to be infringing and its location. Please describe the material, and provide us with its URL or any other pertinent information that will allow us to locate the material. Your name, address, telephone number and (if available) e-mail address.
    A statement that you have a good faith belief that the complained of use of the materials is not authorized by the copyright owner, its agent, or the law.
    A statement that the information that you have supplied is accurate, and indicating that "under penalty of perjury," you are the copyright owner or are authorized to act on the copyright owners behalf.

    A signature or the electronic equivalent from the copyright holder or authorized representative.

    The irosacea.org agent for copyright issues relating to this web site is as follows:

    RRDi Copyright Agent
    PO Box 858
    Centre, Alabama, 35960

    Or use our contact form explaining your copyright issue with our website. We will handle such matters in an appropriate and timely manner. 

    In an effort to protect the rights of copyright owners, the irosacea.org maintains a policy for the termination, in appropriate circumstances, of subscribers and account holders of this web site who are repeat infringers.

    International Disclaimer

    This Web site can be accessed from other countries around the world and may contain references to rosacea products, services, treatments or programs that have not been announced in your country. These references do not imply that irosacea.org intends to announce such products, services or programs in your country.

    Governing Law and Jurisdiction

    This web site (excluding linked sites) is controlled by irosacea.org from its office within the state of Hawaii, United States of America. By accessing this Web site, you and irosacea.org agree that all matters relating to your access to, or use of, this Web site shall be governed by the statutes and laws of the state of Hawaii, without regard to the conflicts of laws principles thereof. You and irosacea.org also agree and hereby submit to the exclusive personal jurisdiction and venue of the Superior Court of the District of Honolulu, Honolulu County and the United States District Court for the District of Hawaii with respect to such matters. irosacea.org makes no representation that materials on this Web site are appropriate or available for use in other locations, and accessing them from territories where their contents are illegal is prohibited. Those who choose to access this site from other locations do so on their own initiative and are responsible for compliance with local laws.

    Privacy Policy

    Our Privacy Policy is the commitment to respect the privacy of the information entrusted to our institute with your personal information by not giving your personal information to others or using it inappropriately. If you have any questions or concerns regarding our privacy policy please direct them to privacy@irosacea.org

    You may also send a letter to:

    Rosacea Research & Development Institute, PO Box 858, Centre, Alabama 35960

    irosacea.org does not sell, exchange, or release your personal information (name, e-mail address, mailing address, credit card data, etc.) without your consent to any third parties.

    Information gathered through the use of cookies is not related to any personally identifiable details.

    What information does irosacea.org collect from our users and how do we collect it?

    irosacea.org only contacts individuals who specifically request that we do so. irosacea.org collects personally identifying information from our users during (1) online registration, (2) online public surveys, (3) online purchasing, and (4) messages posted to our public forum board and the private forum. Generally, this information includes name, e-mail address, postal address, and answers to public survey questions. This information is used for internal purposes and helps us determine how to continually improve our site and the institute. Names and email addresses may be posted in public forums and public databases by individual members who post such information on their own. The RRDi is not responsible if a member posts their own real name, address, phone number, or email address. If a member later regrets posting this information the member can report where the post is and have it removed upon request. If you do not want your name listed in any of the public surveys or databases you should use a bogus name or alias (nickname) since the institute is not responsible if you use your real name or email address in a public survey or database. However, the institute will not publicly display any of the members names, email addresses or postal addresses. Each member is responsible for his or her own privacy when using any of the institute's web site when posting. Non voting members can join the RRDi by providing an email address. 

    Members who donate to the RRDi are named in public financial records unless the donor specifically instructs us that the donation is anonymous.

    Corporate Members Forum Guidelines and Privacy Policy

    The corporate members only private forum is provided as a free service of the RRDi. The institute will not release any names, mailing addresses or email addresses of who is using the private (or public) forum to any third parties without your consent.

    Privacy is important to the RRDi and you can rest assured your contact information is safe with us and we will not disclose your contact info to anyone without your permission or only if we are required by law to disclose your contact info. The privacy policy also includes the Member Forum, Blog and Gallery areas of our site as well as the Tapatalk hosted private form. The Guidelines policy is enforced and binding on all members and guests.

    Blog, Clubs and Gallery

    The Blog, Clubs and Gallery, if available, are provided as a free service by the RRDi to its members only and you are responsible for your own privacy with regard to this service if you engage with another member and disclose your private information in the Blog, Clubs or post photos in the Gallery. The RRDi cannot be held responsible for your privacy if you use the Blog, Clubs or Gallery and our privacy policy, legal disclaimer, rules, and official documents are still binding if you violate this policy.  We warn you to not disclose your private information or post inappropriate content in the Blog, Clubs or Gallery.

    The institute will not release any names or email addresses of who is using the Blog, Clubs or Gallery service without your consent.


    What are cookies and how do we use them?

    Cookies help track a person''s session while online. They are used on our site to gather basic tracking information. Cookies are not related to any personally identifiable information and are not used to retrieve information from your computer that was not originally sent in a cookie.

    Many browsers are set to accept cookies. You may prefer to set your browser to refuse cookies. It is possible, however, that some areas of the site will not function properly if you do so. This is especially likely when trying to order a publication.

    Third-Party Advertising

    Advertisements are not currently allowed on this site. If advertisements are allowed then information about your visits to this site, such as the number of times you have viewed an ad (but not your name, address, or other personal information), is used to serve ads to you. In the course of serving advertisements to this site, third-party advertisers may place or recognize unique cookies on your browser. Links to third-party advertising, or commercial web sites are prohibited.

    Amazon Affiliate

    The RRDi has joined Amazon Affiliates and links to items at amazon.com may be placed throughout the site. The RRDi receives a small fee for each item that is purchased by users who click on an item featured on our site.

    Demodex Solutions Affiliate

    The RRDi has joined the Demodex Solutions affiliate program and links to this program are placed throughout the site. The RRDi receives a small fee for each item that is purchased by users who click on an item featured on our site.


    This policy may be changed at any time at Rosacea Research & Development Institute's discretion.


    © Rosacea Research & Development Institute. All rights reserved. Reproduction, re-transmission or reprinting of the contents of this Web site, in part or in its entirety, is expressly prohibited without prior written permission from the Rosacea Research & Development Institute.

  • Member Statistics

    • Total Members
    • Most Online

    Newest Member
    Richard Trafford-Owen
  • Posts

    • Health Sci Rep. 2023 Sep 25;6(9):e1576. doi: 10.1002/hsr2.1576. eCollection 2023 Sep. ABSTRACT BACKGROUND AND AIM: Metabolic syndrome (MetS) is a well-known noncommunicable disease that plays a significant role in emerging other chronic disorders and following complications. MetS is also involved in the pathophysiology of numerous dermatological diseases. We aim to evaluate the association of MetS with the most prevalent dermatological diseases. METHODS: A systematic search was carried out on PubMed, Science Direct, Web of Science, Cochrane, as well as the Google Scholar search engine. Only English case-control studies regarding MetS and any skin disease from the beginning of 2010 up to November 15, 2022, were selected. The study was conducted based on the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA). RESULTS: A total of 37 studies (13,830 participants) met the inclusion criteria. According to our result, patients with psoriasis, hidradenitis suppurativa (HS), vitiligo, androgenetic alopecia (AGA), and lichen planus (LP) have a higher chance of having MetS compared to the general population. Furthermore, people with seborrheic dermatitis (SED) and rosacea are more prone to insulin resistance, high blood pressure (BP), and higher blood lipids. After pooling data, the meta-analysis revealed a significant association between MetS and skin diseases (pooled odds ratio [OR]: 3.28, 95% confidence interval: 2.62-4.10). Concerning the type of disease, MetS has been correlated with AGA (OR: 11.86), HS (OR: 4.46), LP (OR: 3.79), and SED (OR: 2.45). Psoriasis also showed a significant association but with high heterogeneity (OR: 2.89). Moreover, skin diseases and MetS are strongly associated in Spain (OR: 5.25) and Thailand (OR: 11.86). Regarding the metaregression model, the effect size was reduced with increasing age (OR: 0.965), while the size increased with AGA (OR: 3.064). CONCLUSIONS: MetS is closely associated with skin complications. Dermatologists and other multidisciplinary teams should be cautious while treating these patients to prevent severe complications resulting from MetS. PMID:37752973 | PMC:PMC10519158 | DOI:10.1002/hsr2.1576 {url} = URL to article
    • Skin Res Technol. 2023 Sep;29(9):e13411. doi: 10.1111/srt.13411. NO ABSTRACT PMID:37753697 | DOI:10.1111/srt.13411 {url} = URL to article
    • JMIR Dermatol. 2023 Sep 25;6:e49070. doi: 10.2196/49070. ABSTRACT Case reports serve many functions in the medical literature. We explore patient demographics in case reports for common inflammatory skin diseases. PMID:37747769 | DOI:10.2196/49070 {url} = URL to article
    • Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med. 2023 Aug;31(Special Issue 1):881-886. doi: 10.32687/0869-866X-2023-31-s1-881-886. ABSTRACT Currently, there is an urgent need for global research to develop a modern comprehensive study of rosacea, including its pathogenesis, risk factors, association of rosacea subtypes with concomitant diseases. The most relevant research studies the role of immunity and microorganisms in the pathogenesis of rosacea. To elucidate the features of the comorbidity of rosacea and somatic diseases, studies in various populations with detailed clinical data and a longer follow-up period are important. At the same time, it is important to understand the relationship between the severity and severity of various clinical symptoms of rosacea, the mechanisms that regulate the progression of the process, the combination of rosacea subtypes and the course of the disease in association with other forms of pathological disorders. PMID:37742268 | DOI:10.32687/0869-866X-2023-31-s1-881-886 {url} = URL to article
    • Cureus. 2023 Sep 17;15(9):e45391. doi: 10.7759/cureus.45391. eCollection 2023 Sep. ABSTRACT Granulomatous rosacea is a chronic inflammatory skin disease. We present the case of a 30-year-old woman with a three-month history of erythematous monomorphic papules and nodules on the cheeks and forehead. Histopathological examinations revealed tuberculoid granulomas with multinucleated giant cells. Granulomatous rosacea should be differentiated from other similar granulomatous skin diseases such as cutaneous sarcoidosis and Lupus miliaris disseminates faciei. PMID:37724096 | PMC:PMC10505268 | DOI:10.7759/cureus.45391 {url} = URL to article
    • Front Med (Lausanne). 2023 Sep 1;10:1239869. doi: 10.3389/fmed.2023.1239869. eCollection 2023. ABSTRACT BACKGROUND: Steroid-induced rosacea is a severe withdrawal reaction which can occur after the frequent and excessive topical use of steroids on the face. The Janus kinase (JAK)-signal transducers and activators of transcription signaling pathway is involved in many biological processes and may play a role in the development of steroid-induced rosacea. OBJECTIVE: To observe the efficacy and safety of the JAK1 inhibitor abrocitinib in the treatment of steroid-induced rosacea. METHODS: Four Chinese female patients were treated with orally-administered abrocitinib, a selective JAK1 inhibitor with a good safety profile, for steroid-induced rosacea. RESULTS: Abrocitinib treatment resulted in improved skin condition and lowered Dermatology Life Quality Index scores in each of the four patients. No discomfort was reported and no adverse effects were observed. CONCLUSION: The JAK1 inhibitor abrocitinib is a promising potential treatment for steroid-induced rosacea. PMID:37724178 | PMC:PMC10505430 | DOI:10.3389/fmed.2023.1239869 {url} = URL to article
    • Front Immunol. 2023 Aug 24;14:1211953. doi: 10.3389/fimmu.2023.1211953. eCollection 2023. ABSTRACT INTRODUCTION: Rosacea, a widespread chronic skin condition, may be influenced by macrophages, key immune cells in the skin, although their exact role is not yet fully understood. This review delves into the function of macrophages, their potential contribution to rosacea pathogenesis, current treatments, and promising macrophage-targeted therapies. It concludes by identifying knowledge gaps and potential areas for future rosacea research. METHOD: Leveraging systematic and narrative literature review techniques, we conducted a comprehensive search of databases such as PubMed, Embase, and Web of Science. Utilizing keywords like "rosacea" and "macrophages", we targeted English articles from the last 5 years (2018-2023). We manually checked reference lists of relevant articles for additional studies. We included only articles emphasizing macrophages' role in rosacea and/or the development of related therapies and published within the specified timeframe. RESULTS: The systematic search of electronic databases yielded a total of 4,263 articles. After applying the inclusion and exclusion criteria, 156 articles were selected for inclusion in this review. These articles included original research studies, review articles, and clinical trials that focused on the role of macrophages in rosacea and/or the development of macrophage-targeted therapies for the disease. The selected articles provided a comprehensive and up-to-date overview of the current state of research on macrophages in rosacea, including their function in the skin, the potential mechanisms through which they may contribute to rosacea pathogenesis, and the current treatments and therapies available for the disease. Additionally, the articles identified gaps in knowledge regarding the role of macrophages in rosacea and suggested potential areas for future research. CONCLUSION: This literature review emphasizes the important role that macrophages, vital immune cells in the skin, may play in the pathogenesis of rosacea, a common chronic inflammatory skin disorder. The selected studies suggest potential mechanisms by which these cells might contribute to rosacea progression, although these mechanisms are not yet fully understood. The studies also spotlight current rosacea treatments and illuminate the promising potential of new macrophage-focused therapies. Despite these insights, significant gaps persist in our understanding of the precise role of macrophages in rosacea. Future research in this area could provide further insights into the pathogenesis of rosacea and contribute to the development of more effective, targeted therapeutic strategies. PMID:37691916 | PMC:PMC10484341 | DOI:10.3389/fimmu.2023.1211953 {url} = URL to article
    • Arch Soc Esp Oftalmol (Engl Ed). 2023 Sep 9:S2173-5794(23)00149-4. doi: 10.1016/j.oftale.2023.09.001. Online ahead of print. ABSTRACT Rosacea is a chronic and inflammatory disease that primarily affects the skin, although more than half of cases also present with ocular symptoms ranging from blepharitis to conjunctivitis and keratitis. It represents a frequent reason for consultation with a psychosocial impact, affecting quality of life, and requires management involving ophthalmologists, dermatologists, and primary care physicians. For this paper, a search was conducted in several databases, including Medline, Embase, Cochrane, and Google Scholar, using the MeSH term "rosacea" in conjunction with other relevant keywords such as "ocular rosacea", "management", "treatment", and "guidelines". Available articles were reviewed. International and local guidelines recommend initiating the management of rosacea with lifestyle changes, including ocular hygiene and avoidance of triggers. Topical or oral treatment is recommended as the next step, with topical cyclosporine, topical azithromycin, topical tacrolimus, and oral doxycycline being the treatments most supported by evidence. Combination treatments are also recommended. Current management guidelines mainly focus on cutaneous manifestations, generating few guidelines on ophthalmologic treatment, and most recommendations are issued by experts. This work compares local and international treatment guidelines for rosacea, as well as other available medical literature, and suggests a practical and interdisciplinary treatment scheme for ocular involvement based on the reviewed bibliography. PMID:37696488 | DOI:10.1016/j.oftale.2023.09.001 {url} = URL to article
    • Nutrients. 2023 Aug 30;15(17):3803. doi: 10.3390/nu15173803. ABSTRACT BACKGROUND: Previous cross-sectional studies have failed to definitively establish a causal relationship between serum 25-hydroxyvitamin D (25OHD) concentrations and the onset of rosacea. OBJECTIVE: To investigate the potential association between serum 25OHD levels, vitamin D receptor (VDR) polymorphisms, and the risk of developing incident rosacea. METHODS: This cross-sectional population-based cohort study utilizing 370,209 individuals from the UK Biobank. Cox proportional hazard regression models and two-sample Mendelian randomization (MR) analyses were applied to explore the causative relationship between 25OHD and incident rosacea. RESULTS: Our findings revealed that elevated levels of serum 25OHD were inversely correlated with the risk of incident rosacea. Specifically, compared to participants with 25OHD levels below 25 nmol/L, the multivariate-adjusted HR for incident rosacea was 0.81 (95% CI: 0.70, 0.94) in those with 25OHD levels exceeding 50 nmol/L. Further, in comparison to individuals with serum 25OHD less than 25 nmol/L and the rs731236 (TaqI) AA allele, those with serum 25OHD higher than 75 nmol/L and the TaqI GG allele had a multivariate-adjusted HR of 0.51 (95% CI 0.32 to 0.81) for developing rosacea. Results from the MR study supported a significant association, with each standard deviation increase in serum 25OHD concentrations correlating to a 23% reduced risk of rosacea (HR = 0.77, 95% CI: 0.63, 0.93). CONCLUSIONS: The findings of this cohort study indicate an inverse association between increased concentrations of serum 25OHD and the risk of developing incident rosacea. While our results highlight the potential protective role of vitamin D, the definitive efficacy of vitamin D supplementation as a preventive strategy against rosacea requires further investigation. PMID:37686836 | PMC:PMC10489658 | DOI:10.3390/nu15173803 {url} = URL to article
    • Sci Rep. 2023 Sep 9;13(1):14910. doi: 10.1038/s41598-023-42073-6. ABSTRACT The association between rosacea and inflammatory bowel disease (IBD) has been studied in previous observational studies. It is unclear, however, whether the association is causal or not. Independent genetic variants for IBD were chosen as instruments from published Genome-wide association studies (GWAS) studies involving 38,155 cases with an IBD diagnosis and 48,485 controls in order to investigate the causal effect of IBD on rosacea. Summarized data for rosacea were gathered from various GWAS studies that included 1195 cases and 211,139 controls without rosacea. Reverse-direction Mendelian randomization (MR) analysis was done to investigate the relationship between genetically proxied rosacea and IBD. With the use of the inverse variance-weighted (IVW), MR-Egger, and weighted median approaches, a 2-sample Mendelian randomization study was carried out. Analysis of heterogeneity and sensitivity was performed to examine the pleiotropy and robustness of effect estimates. The forward-direction of the MR study was to reveal that genetic predisposition to IBD including its two main subtypes: Crohn's disease (CD) and ulcerative colitis (UC) was associated with an increased risk of rosacea. The reverse-direction MR analyses did not demonstrate that a genetic predisposition to rosacea was associated with total IBD, UC and CD. Our findings provided evidence for a causal impact of IBD, UC, and CD on rosacea, but not vice versa. The elevated incidence of rosacea in patients with IBD should be recognized by doctors to make an early diagnosis and initiate specialized therapy. PMID:37689807 | PMC:PMC10492847 | DOI:10.1038/s41598-023-42073-6 {url} = URL to article
    • Clin Ter. 2023 Sep-Oct;174(5):404-411. doi: 10.7417/CT.2023.2457. ABSTRACT BACKGROUND: Understanding the connection between skin lesions and the pathology of internal organs and body systems that may have caused them is a prerequisite for successful cosmetic therapy. AIM: The aim of this study was to analyze the influence of a patient's somatic pathology on the manifestation of skin abnormalities. MATERIALS AND METHODS: The study was conducted according to a "case-control" design and was accompanied by a retrospective study of outpatient records of patients with the disease (group 1) and patients without it (control group). It is aimed at revealing the connection between a patient's skin manifestations and somatic pathology, as well as the effectiveness of therapeutic measures for the correction of such a condition. RESULTS: Patients with acne and rosacea have a statistically signi-ficantly higher incidence of gastrointestinal diseases (in particular, gastritis caused by Helicobacter), diabetes mellitus, vitamin and micronutrient deficiencies, which significantly affects the effectiveness of their treatment and quality of life. In such chronic dermatoses, disruption of intestinal microbiocenosis can be considered as a co-morbid condition. Hyperpigmentation of patients' skin was caused by hormonal dysfunction (hyperestrogenism) and was accompanied by vitamin D deficiency. CONCLUSIONS: In cosmetology practice, therapy of dermatoses should be individualized and based on the analysis of the course of the disease, considering the diagnosed dysfunctions of certain organs or systems that cause skin pathological changes, as well as the preva-lence and severity of dermatosis, presence of comorbid background and mental disorders. A holistic approach in the therapy of dermatoses involving a dermatologist, a psychologist, a cosmetologist, and specialized clinicians will ensure their effective treatment. PMID:37674449 | DOI:10.7417/CT.2023.2457 {url} = URL to article
    • Front Pain Res (Lausanne). 2023 Aug 22;4:1273636. doi: 10.3389/fpain.2023.1273636. eCollection 2023. NO ABSTRACT PMID:37674769 | PMC:PMC10478075 | DOI:10.3389/fpain.2023.1273636 {url} = URL to article
  • Create New...

Important Information

Terms of Use